|
1.
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ,
Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M,
Lacombe D, Cairncross JG and Mirimanoff RO; European Organisation
for Research and Treatment of Cancer Brain Tumour and Radiation
Oncology Groups and National Cancer Institute of Canada Clinical
Trials Group: Effects of radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC
trial. Lancet Oncol. 10:459–466. 2009.
|
|
2.
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe
G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W,
Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN,
Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW,
Meyerson M, Getz G, Perou CM and Hayes DN; Cancer Genome Atlas
Research Network: Integrated genomic analysis identifies clinically
relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR and NF1. Cancer Cell. 17:98–110. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW,
Velculescu VE, Vogelstein B and Bigner DD: IDH1 and IDH2 mutations
in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Shinojima N, Tada K, Shiraishi S, Kamiryo
T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka
K, Ishimaru Y and Ushio Y: Prognostic value of epidermal growth
factor receptor in patients with glioblastoma multiforme. Cancer
Res. 63:6962–6970. 2003.PubMed/NCBI
|
|
5.
|
Ekstrand AJ, James CD, Cavenee WK, Seliger
B, Pettersson RF and Collins VP: Genes for epidermal growth factor
receptor, transforming growth factor alpha, and epidermal growth
factor and their expression in human gliomas in vivo. Cancer Res.
51:2164–2172. 1991.PubMed/NCBI
|
|
6.
|
Wikstrand CJ, McLendon RE, Friedman AH and
Bigner DD: Cell surface localization and density of the
tumor-associated variant of the epidermal growth factor receptor,
EGFRvIII. Cancer Res. 57:4130–4140. 1997.PubMed/NCBI
|
|
7.
|
Ekstrand AJ, Longo N, Hamid ML, Olson JJ,
Liu L, Collins VP and James CD: Functional characterization of an
EGF receptor with a truncated extracellular domain expressed in
glioblastomas with EGFR gene amplification. Oncogene. 9:2313–2320.
1994.PubMed/NCBI
|
|
8.
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wheeler SE, Suzuki S, Thomas SM, Sen M,
Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY
and Grandis JR: Epidermal growth factor receptor variant III
mediates head and neck cancer cell invasion via STAT3 activation.
Oncogene. 29:5135–5145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Nishikawa R, Ji XD, Harmon RC, Lazar CS,
Gill GN, Cavenee WK and Huang HJ: A mutant epidermal growth factor
receptor common in human glioma confers enhanced tumorigenicity.
Proc Natl Acad Sci USA. 91:7727–7731. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Tang CK, Gong XQ, Moscatello DK, Wong AJ
and Lippman ME: Epidermal growth factor receptor vIII enhances
tumorigenicity in human breast cancer. Cancer Res. 60:3081–3087.
2000.PubMed/NCBI
|
|
12.
|
Theys J, Jutten B, Dubois L, Rouschop KM,
Chiu RK, Li Y, Paesmans K, Lambin P, Lammering G and Wouters BG:
The deletion mutant EGFRvIII significantly contributes to stress
resistance typical for the tumour microenvironment. Radiother
Oncol. 92:399–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sok JC, Coppelli FM, Thomas SM, Lango MN,
Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD,
Gooding WE, Furnari FB and Grandis JR: Mutant epidermal growth
factor receptor (EGFRvIII) contributes to head and neck cancer
growth and resistance to EGFR targeting. Clin Cancer Res.
12:5064–5073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ekstrand AJ, Sugawa N, James CD and
Collins VP: Amplified and rearranged epidermal growth factor
receptor genes in human glioblastomas reveal deletions of sequences
encoding portions of the N- and/or C-terminal tails. Proc Natl Acad
Sci USA. 89:4309–4313. 1992. View Article : Google Scholar
|
|
15.
|
Frederick L, Eley G, Wang XY and James CD:
Analysis of genomic rearrangements associated with EGRFvIII
expression suggests involvement of Alu repeat elements. Neuro
Oncol. 2:159–163. 2000.PubMed/NCBI
|
|
16.
|
Pines G, Huang PH, Zwang Y, White FM and
Yarden Y: EGFRvIV: a previously uncharacterized oncogenic mutant
reveals a kinase autoinhibitory mechanism. Oncogene. 29:5850–5860.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Cho J, Pastorino S, Zeng Q, Xu X, Johnson
W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon
J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S and Meyerson M:
Glioblastoma-derived epidermal growth factor receptor
carboxyl-terminal deletion mutants are transforming and are
sensitive to EGFR-directed therapies. Cancer Res. 71:7587–7596.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Frederick L, Wang XY, Eley G and James CD:
Diversity and frequency of epidermal growth factor receptor
mutations in human glioblastomas. Cancer Res. 60:1383–1387.
2000.PubMed/NCBI
|
|
19.
|
Yoshimoto K, Dang J, Zhu S, Nathanson D,
Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H,
Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK,
Cloughesy TF and Mischel PS: Development of a real-time RT-PCR
assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer
Res. 14:488–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Newcomb EW, Cohen H, Lee SR, Bhalla SK,
Bloom J, Hayes RL and Miller DC: Survival of patients with
glioblastoma multi-forme is not influenced by altered expression of
p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 8:655–667. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Sonnweber B, Dlaska M, Skvortsov S,
Dirnhofer S, Schmid T and Hilbe W: High predictive value of
epidermal growth factor receptor phosphorylation but not of
EGFRvIII mutation in resected stage I non-small cell lung cancer
(NSCLC). J Clin Pathol. 59:255–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Nieto Y, Nawaz F, Jones RB, Shpall EJ and
Nawaz S: Prognostic significance of overexpression and
phosphorylation of epidermal growth factor receptor (EGFR) and the
presence of truncated EGFRvIII in locoregionally advanced breast
cancer. J Clin Oncol. 25:4405–4413. 2007. View Article : Google Scholar
|
|
23.
|
Heimberger AB, Hlatky R, Suki D, Yang D,
Weinberg J, Gilbert M, Sawaya R and Aldape K: Prognostic effect of
epidermal growth factor receptor and EGFRvIII in glioblastoma
multiforme patients. Clin Cancer Res. 11:1462–1466. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Aldape KD, Ballman K, Furth A, Buckner JC,
Giannini C, Burger PC, Scheithauer BW, Jenkins RB and James CD:
Immunohistochemical detection of EGFRvIII in high malignancy grade
astrocytomas and evaluation of prognostic significance. J
Neuropathol Exp Neurol. 63:700–707. 2004.PubMed/NCBI
|
|
25.
|
Mellinghoff IK, Wang MY, Vivanco I,
Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute
DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R,
Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF,
Sawyers CL and Mischel PS: Molecular determinants of the response
of glioblastomas to EGFR kinase inhibitors. N Engl J Med.
353:2012–2024. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Li L, Dutra A, Pak E, Labrie JE 3rd,
Gerstein RM, Pandolfi PP, Recht LD and Ross AH: EGFRvIII expression
and PTEN loss synergistically induce chromosomal instability and
glial tumors. Neuro Oncol. 11:9–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Haas-Kogan DA, Prados MD, Lamborn KR,
Tihan T, Berger MS and Stokoe D: Biomarkers to predict response to
epidermal growth factor receptor inhibitors. Cell Cycle.
4:1369–1372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Haas-Kogan DA, Prados MD, Tihan T,
Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia
A, Malec M, Berger MS and Stokoe D: Epidermal growth factor
receptor, protein kinase B/Akt, and glioma response to erlotinib. J
Natl Cancer Inst. 97:880–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
van den Bent MJ, Brandes AA, Rampling R,
Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M,
Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H,
Klughammer B, Lacombe D and Gorlia T: Randomized phase II trial of
erlotinib versus temozolomide or carmustine in recurrent
glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol.
27:1268–1274. 2009.PubMed/NCBI
|
|
30.
|
Jeuken J, Sijben A, Alenda C, Rijntjes J,
Dekkers M, Boots-Sprenger S, McLendon R and Wesseling P: Robust
detection of EGFR copy number changes and EGFR variant III:
technical aspects and relevance for glioma diagnostics. Brain
Pathol. 19:661–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Patel D, Lahiji A, Patel S, Franklin M,
Jimenez X, Hicklin DJ and Kang X: Monoclonal antibody cetuximab
binds to and down-regulates constitutively activated epidermal
growth factor receptor vIII on the cell surface. Anticancer Res.
27:3355–3366. 2007.
|
|
32.
|
Eller JL, Longo SL, Hicklin DJ and Canute
GW: Activity of anti-epidermal growth factor receptor monoclonal
antibody C225 against glioblastoma multiforme. Neurosurgery.
51:1005–1013. 2002.PubMed/NCBI
|
|
33.
|
Eller JL, Longo SL, Kyle MM, Bassano D,
Hicklin DJ and Canute GW: Anti-epidermal growth factor receptor
monoclonal antibody cetuximab augments radiation effects in
glioblastoma multiforme in vitro and in vivo. Neurosurgery.
56:155–162. 2005.
|
|
34.
|
Neyns B, Sadones J, Joosens E, Bouttens F,
Verbeke L, Baurain JF, D’Hondt L, Strauven T, Chaskis C, In’t Veld
P, Michotte A and De Greve J: Stratified phase II trial of
cetuximab in patients with recurrent high-grade glioma. Ann Oncol.
20:1596–1603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Lv S, Teugels E, Sadones J, Quartier E,
Huylebrouck M, Du Four S, Le Mercier M, De Witte O, Salmon I,
Michotte A, De Greve J and Neyns B: Correlation between IDH1 gene
mutation status and survival of patients treated for recurrent
glioma. Anticancer Res. 31:4457–4463. 2011.PubMed/NCBI
|
|
37.
|
Loupakis F, Pollina L, Stasi I, Ruzzo A,
Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E,
Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G,
Campani D, Floriani I, Cascinu S and Falcone A: PTEN expression and
KRAS mutations on primary tumors and metastases in the prediction
of benefit from cetuximab plus irinotecan for patients with
metastatic colorectal cancer. J Clin Oncol. 27:2622–2629. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Mason WP and Cairncross JG: Invited
article: the expanding impact of molecular biology on the diagnosis
and treatment of gliomas. Neurology. 71:365–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Fults D and Pedone C: Immunocytochemical
mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor
suppressor protein in human gliomas. Neuro Oncol. 2:71–79.
2000.PubMed/NCBI
|
|
40.
|
de Groot JF, Gilbert MR, Aldape K, Hess
KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli
VK, Levin V and Yung WK: Phase II study of carboplatin and
erlotinib (Tarceva, OSI-774) in patients with recurrent
glioblastoma. J Neurooncol. 90:89–97. 2008.PubMed/NCBI
|
